Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Tapimmune's phase II study of TPIV-200 in TNBC cleared to continue

Feb. 16, 2017

TREOS Bio raises funds to support clinical trial of colorectal cancer vaccine

Feb. 16, 2017

Amgen submits sBLA to FDA for Blincyto

Feb. 15, 2017

Incyte and Agenus amend 2015 license, development and commercialization agreement

Feb. 15, 2017

MVT-5873 plus PEGPH-20 shows promising results in animal model of pancreatic cancer

Feb. 14, 2017

Inovio enters agreement with ApolloBio regarding VGX-3100

Feb. 14, 2017

Merck Sharp & Dohme begins phase I testing of MK-1454 in advanced solid tumors, lymphomas

Feb. 13, 2017

Seattle Genetics and Immunomedics enter global license agreement for sacituzumab govitecan

Feb. 13, 2017

Boehringer Ingelheim starts phase II trial to treat advanced squamous cell carcinoma of the lung

Feb. 10, 2017

Tessa Therapeutics and A*STAR's IMCB collaborate on immuno-oncology lab

Feb. 10, 2017

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 9, 2026.
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Hyperexcitability may be joint problem in epilepsy, dementia
BioWorld
The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
GDE4 blockade promotes remyelination, study finds
BioWorld Science
Myelin is crucial for the correct functioning of nerve signaling and its loss is a feature of neurological disorders. The cells responsible for myelination in the...